A group of researchers from Korea and U.S.A conducted a study to  examine site-specific cancer incidence and mortality and to evaluate the  radiation dose-response association after RAI treatment for hyperthyroidism.
    Study inclusion criteria were as follows: 
    (1)  inclusion of patients treated for hyperthyroidism with RAI and  followed up until cancer diagnosis or death
    (2)  inclusion of at least 1 comparison group composed of individuals  unexposed to RAI treatment or those exposed to different administered doses of  RAI
    (3)  inclusion of effect size measures 
    Two independent investigators extracted data according to the  Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines.  Overall quality assessment followed the recommendations of United Nations  Scientific Committee on the Effects of Atomic Radiation. The SIR and SMRs and  the RRs and HRs were pooled using random-effects meta-analysis.
    The primary outcomes were Cancer incidence and mortality for  exposure vs non-exposure to RAI therapy and by the level of RAI administered  activity.
    The results of the study are as follows:
    ·         Based on data from 12  studies including 479 452 participants, the overall pooled cancer incidence ratio was 1.02 and the pooled cancer mortality ratio was 0.98 for exposure vs  non-exposure to RAI therapy. 
    ·         No statistically significant  elevations in risk were observed for specific cancers except for thyroid cancer  incidence and mortality.
    ·         However, the inability to  control for confounding by indication and other sources of bias were important  limitations of studies comparing RAI exposure with non-exposure. 
    ·         In dose-response analysis,  RAI was significantly associated with breast and solid cancer mortality, based  on 2 studies.
    Thus, the researchers concluded that that radiation-induced  cancer risks following RAI therapy for hyperthyroidism are small and, in  observational studies may only be detectable at higher levels of administered  dose.
    Reference:
    Cancer Risk After Radioactive Iodine Treatment for  Hyperthyroidism: A Systematic Review and Meta-analysis by Shim S et. al  published in the JAMA Netw Open. 
    doi:10.1001/jamanetworkopen.2021.25072
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.